Investigational Drug Information for Tariquidar
✉ Email this page to a colleague
What is the development status for investigational drug Tariquidar?
Tariquidar is an investigational drug.
There have been 10 clinical trials for Tariquidar.
The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2002.
The most common disease conditions in clinical trials are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, and Neuralgia. The leading clinical trial sponsors are National Cancer Institute (NCI), QLT Inc., and Washington University School of Medicine.
Summary for Tariquidar
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 1,443 |
| WIPO Patent Applications | 644 |
| Japanese Patent Applications | 45 |
| Clinical Trial Progress | Phase 2 (2002-06-01) |
| Vendors | 64 |
Recent Clinical Trials for Tariquidar
| Title | Sponsor | Phase |
|---|---|---|
| Tariquidar-ondansetron Combination in Neuropathic Pain | Washington University School of Medicine | Phase 1/Phase 2 |
| Pgp Transporter and CNS Biodistribution of Ondansetron in Healthy Volunteers | Washington University School of Medicine | Phase 1 |
| Paclitaxel and CBT-1(Registered Trademark) to Treat Solid Tumors | National Cancer Institute (NCI) | N/A |
Clinical Trial Summary for Tariquidar
Top disease conditions for Tariquidar
Top clinical trial sponsors for Tariquidar
US Patents for Tariquidar
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
